Apoptosis
Apoptosis(凋亡)
As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.
Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.
Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.
Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.
Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.
Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.
One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.
p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9).
Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.
References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.
- Caspase(102)
- 14.3.3 Proteins(2)
- Apoptosis Inducers(45)
- Bax(7)
- Bcl-2 Family(122)
- Bcl-xL(8)
- c-RET(9)
- IAP(27)
- KEAP1-Nrf2(67)
- MDM2(15)
- p53(128)
- PC-PLC(5)
- PKD(8)
- RasGAP (Ras- P21)(1)
- Survivin(8)
- Thymidylate Synthase(10)
- TNF-α(151)
- Other Apoptosis(900)
- Apoptosis Detection
- Caspase Substrate
- APC(6)
- PD-1/PD-L1 interaction(91)
- ASK1(3)
- PAR4(2)
- RIP kinase(52)
- FKBP(20)
- Pyroptosis(32)
Apoptosis 相关产品(2721)
- GC14411ApoptozoleCAS: 1054543-47-3纯度: >99.50%
Apoptozole是一种小分子抑制剂,可靶向HSC70和HSP72,K D 值分别为210nM和140nM。
- GC14533Kynurenic acidCAS: 492-27-3纯度: >99.00% / >98.00%
Kynurenic acid 是一种内源性色氨酸代谢物,是一种针对 NMDA、谷氨酸、α7 烟碱乙酰胆碱受体的广谱拮抗剂。
- GC14622Diclofenac PotassiumCAS: 15307-81-0纯度: >98.00%
Diclofenac Potassium是一种强效的非选择性环氧化酶(COX)抑制剂,在CHO细胞中对人源COX-1和COX-2的IC₅₀值分别为4nM和1.3nM;对羊源COX-1和COX-2的IC₅₀值分别为5.1μM和0.84μM。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC14409 | ZM 447439 | 331771-20-1 | >98.00% | |
Selective inhibitor of Aurora B kinase | ||||
| GC14411 | Apoptozole | 1054543-47-3 | >99.50% | |
Apoptozole是一种小分子抑制剂,可靶向HSC70和HSP72,K D 值分别为210nM和140nM。 | ||||
| GC14485 | Dacarbazine | 4342-03-4 | >98.00% | |
A DNA alkylating prodrug | ||||
| GC14488 | NPS-1034 | 1221713-92-3 | >98.00% | |
A dual MET/AXL inhibitor | ||||
| GC14498 | AP20187 | 195514-80-8 | >98.00% | |
AP20187是一种合成的二聚体化合物,能够诱导含有FKBP(FK506结合蛋白)结构域的蛋白质发生二聚化。AP20187在多种生物学研究和治疗中被用于控制蛋白质-蛋白质相互作用和调节细胞过程。 | ||||
| GC14499 | Fenoprofen calcium hydrate | 71720-56-4 | >99.50% | |
An NSAID | ||||
| GC14500 | CPI-1189 | 183619-38-7 | - | |
A benzamide | ||||
| GC14503 | IC261 | 186611-52-9 | >99.50% | |
A reversible inhibitor of CK1 | ||||
| GC14533 | Kynurenic acid | 492-27-3 | >99.00% / >98.00% | |
Kynurenic acid 是一种内源性色氨酸代谢物,是一种针对 NMDA、谷氨酸、α7 烟碱乙酰胆碱受体的广谱拮抗剂。 | ||||
| GC14534 | Regorafenib monohydrate | 1019206-88-2 | >99.50% | |
A multi-kinase inhibitor | ||||
| GC14553 | Resveratrol | 501-36-0 | >99.50% | |
白藜芦醇(转-白藜芦醇;SRT501)是一种植物抗菌素。 | ||||
| GC14561 | SCH 529074 | 922150-11-6 | >98.00% | |
An activator of p53 | ||||
| GC14566 | CCT137690 | 1095382-05-0 | >99.00% | |
An inhibitor of Aurora kinases and FLT3 | ||||
| GC14590 | AR-42 (OSU-HDAC42) | 935881-37-1 | - | |
HDAC inhibitor,novel and potent | ||||
| GC14592 | KW 2449 | 1000669-72-6 | >99.50% | |
A multi-kinase inhibitor | ||||
| GC14606 | Regorafenib hydrochloride | 835621-07-3 | >99.50% | |
A multi-kinase inhibitor | ||||
| GC14622 | Diclofenac Potassium | 15307-81-0 | >98.00% | |
Diclofenac Potassium是一种强效的非选择性环氧化酶(COX)抑制剂,在CHO细胞中对人源COX-1和COX-2的IC₅₀值分别为4nM和1.3nM;对羊源COX-1和COX-2的IC₅₀值分别为5.1μM和0.84μM。 | ||||
| GC14631 | SP2509 | 1423715-09-6 | >99.50% | |
A reversible inhibitor of LSD1 | ||||
| GC14634 | CBL0137 | 1197996-80-7 | >98.00% | |
CBL0137是一种靶向FACT复合体以调节染色质结构和基因表达的first-in-class小分子化合物,可靶向抑制NF-κB信号通路活性,具有抗癌和抗炎特性。 | ||||
| GC14644 | SBE 13 HCl | 1052532-15-6 | >98.50% | |
A potent Plk1 inhibitor | ||||
| GC14675 | WYE-125132 (WYE-132) | 1144068-46-1 | >99.00% | |
Dual mTORC1/mTORC2 inhibitor | ||||
| GC14681 | Nolatrexed (AG-337) | 152946-68-4 | >98.50% | |
A thymidylate synthase inhibitor | ||||
| GC14699 | CPI-203 | 1446144-04-2 | >99.00% | |
A bioavailable inhibitor of BET bromodomains | ||||
| GC14707 | Purvalanol A | 212844-53-6 | >99.00% | |
A selective inhibitor of cyclin-dependent kinases | ||||
